In India, Covishield and Covaxin are being utilized to vaccinate people against the deadly coronavirus. Covaxin has been developed by Bharat Biotech whereas Serum Institute has developed the Covishield. Some difference can be seen with both the vaccine quite naturally. However, there are few similarities as well.
Following to the vaccination of the healthcare workers all over the India, officials have started to vaccinate elderly people over the age of 60 in addition to people with co-morbidity.
Technology of Whole-Virion Inactivated Vero Cell derived platform has been utilized. Replication is not seen on the occasion. Therefore, revert process may not be observed at all. Pathological effects may not be caused also. Use of dead virus is noticed that may not be capable of infecting people. However, immune system is instructed to create a defense against a possible infection.
For more than a decade, use of inactive vaccine can be noticed in the medical arena. Several vaccines have been created for polio, rabies, influenza, Japanese encephalitis and pertussis by using the same technology in the past.
Regarding Covishield, use of viral vector platform can be observed. On the occasion, chimpanzee adenovirus named ChAdOx1 is utilized as a vector. Later on, it has been modified to carry forward the spike protein of the coronavirus to the human cells. Cold virus injected in the body is completely harmless. However, an instruction module is used to fight it out with the coronavius and other similar kind of virus. To the body, instruction is given to protect you against coronavirus and other viruses. It is a platform that has been utilized after the outbreak of Ebola as well.
Regime for Dosage
Requirement of sub-zero temperature may not be needed for storage with both the vaccines. It is a liquid that comes in a multi-dose vial. To keep the vaccine safe, it has to be stored in 2 to 8 degree Celsius.
During studies, Covaxin has shown protective and strong immunogenicity in the animals like hamster and other primate animals. However, efficacy percentage is still not available for the human yet as phase III trials have not been completed.
In case of Covishield, 62% of efficacy can be noticed.
In case of Covaxin, authorization is given for restricted use during a clinical trial mode
Both Covaxin and Covisheild is intramuscular vaccine that are being given from Governmental Hospital at free of cost. However, private hospitals can be about Rs. 250 for the vaccination.